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Abstract
Oestrogen (E2) is an important regulator of bone cell function and alterations in oestrogen levels may cause abnormal bone
metabolism in vivo. In this study we examined the long term effects of 17L-oestradiol (17L-E2) on G-proteins and the
secondary signalling pathways of phospholipase C (PLC), cyclic adenosine monophosphate (cAMP), and 1,4,5-inositol
triphosphate (IP3). Cells from neonatal mouse calvariae were cultured in phenol red-free RPMI 1640 medium supplemented
with charcoal stripped foetal calf serum for 192 h with either oestrogen (1038 M), or oestrogen withdrawal after 48 h.
Cultures were stimulated for the final 48 h with IL-6 (10310 M), or left unstimulated. Western blot analysis was undertaken
on osteoblast membrane preparations obtained by 10 mM Tris-HCl, 0.1 mM EDTA pH 7.8 and centrifugation at 40 000Ug
for 2 h. For cAMP study, cells were stimulated with IL-6 for either 15 min or 30 min. Intracellular cAMP was extracted from
cells and measured by ELISA methodology. For the IP3 assay, cells were stimulated with IL-6 for 20 s and IP3 levels
measured using radioimmunoassay. The blots revealed increased levels of GiK-, and GqK-proteins with oestrogen withdrawal
and IL-6 stimulation. This was in comparison to cells which were unstimulated, or stimulated with IL-6 with continuous 17L-
E2, or IL-6 alone. GsK expression decreased with oestrogen withdrawal compared to the control. Limited amounts of GiK-,
GsK-, and GqK-proteins were identified with continuous 17L-E2. The levels of PLC isoforms PLCL1ÿ2 were not affected by
the differing oestrogen conditions. The cAMP production induced by IL-6 stimulation for 30 min and withdrawal of 17L-E2
was lower and significantly different compared to the control study (P6 0.05). Also IL-6 activation with continuous
oestradiol increased cAMP levels and was significantly different from the control cells (P6 0.01). However, 17L-E2 had no
effect on the formation of intracellular IP3, although IL-6 significantly lowered IP3 levels in all the groups compared to the
control (P6 0.01). These results suggest that oestrogen modulates the signal transduction pathways of G-protein molecules,
and the secondary pathways of cAMP in mouse osteoblast-like cells. ß 1999 Elsevier Science B.V. All rights reserved.
1. Introduction
Oestrogen is a key factor in bone remodelling and
the loss of oestrogen either from natural or surgically
induced menopause results in high turnover bone
loss in both animals and humans leading to osteopo-
rosis [1,2]. High a⁄nity oestrogen nuclear receptors
are present in both osteoblasts [3] and osteoclasts [4]
suggesting oestrogen can act directly on bone cells.
Recent data suggest that oestrogen regulates the pro-
duction of cytokines, particularly those responsible
for bone remodelling. These data include interleu-
kin-1 (IL-1), tumour necrosis factor-K (TNF-K) and
interleukin-6 (IL-6), whose synthesis by osteoblasts
and bone marrow stromal cells is down-regulated
by 17L-E2 [5], although, following loss of ovarian
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function, IL-6 production is increased in ex vivo cul-
tures of marrow cells from ovariectimized mice com-
pared with cultures of marrow cells from sham-oper-
ated animals [6]. Furthermore, loss of ovarian
function in mice causes an up-regulation of osteo-
clast precursor formation in the marrow and an in-
crease in the number of osteoclasts in trabecular
bone, changes that are preventable by either IL-6
antibody or 17L-E2 [7]. IL-6-de¢cient mice do not
lose bone upon ovariectomy [8], suggesting that in
the oestrogen-replete state IL-6 is not essential for
promoting osteoclastogenesis.
The signal transduction pathway by which oestro-
gen in£uences bone cells during bone remodelling
remains essentially incomplete. One of the compo-
nents of the intracellular signalling mechanism is
the group of heterotrimeric G-proteins that are at-
tached to the cytoplasmic surface of the plasma
membrane [9,10]. A number of studies have shown
that some ligands involved in bone metabolism in-
duce their e¡ects on osteoblasts via these receptor-
bound G-proteins. These include parathyroid hor-
mone (PTH) [11,12], prostaglandins [13,14] and insu-
lin-like growth factor II [15]. This activation in turn
results in the secretion of proteins, cell di¡erentiation
and proliferation. Also, these ligands have the poten-
tial to stimulate de novo bone formation via the
G-proteins. High doses of PTH stimulate this bone
formation by recruiting new osteoblasts which gen-
erate new trabecular structures [12,16^18]. The pre-
dominant e¡ect of intermittent PTH treatment is to
increase the thickness of existing trabeculae, suggest-
ing an e¡ect on mature osteoblasts lining bone struc-
tures [19].
The G-proteins involved in signalling are made of
K, L, and Q subunits, and although there are many
gene products encoding each subunit (20 K, six L,
and 12 Q gene products are known), four main classes
of G-proteins can be distinguished (GsK, GiK, GqK,
G12ÿ13K [9,10]. In osteoblasts the following have
been identi¢ed: (1) GsK, which activates adenylyl
cyclase and in so doing stimulates cAMP produc-
tion; (2) GiK which inhibits cAMP production by
suppressing stimulation of adenylyl cyclase; (3)
GqK which activates the secondary messenger phos-
pholipase CL which generates IP3 and diacylglycerol
[20].
The aim of this study was to evaluate the e¡ects of
changing oestrogen conditions on the speci¢c aspects
of signal transduction pathways involving G-proteins
in mouse osteoblasts. Namely the levels of expression
of speci¢c G-proteins were established. Subsequently
intracellular secondary messengers were assayed in
order to identify whether changes in the expression
of-G proteins were associated with subsequent cellu-
lar activation.
2. Materials and methods
2.1. Materials
Mice were purchased from Charles Rivers (UK).
Culture media and charcoal stripped foetal calf se-
rum (CSFCS) were obtained from Gibco BRL (UK).
General laboratory chemicals and reagents were ob-
tained from Sigma-Aldrich (Poole, Dorset, UK).
Plastic ware for tissue culture was obtained from
Corning Coster (High Wycombe, UK) and chamber
slides from Labtek (Nunc, Naperville, IL, USA).
2.2. Methods
Due to the complexity of the protocol the overall
study is detailed in Fig. 1. Essentially the following
protocol involves mouse osteoblasts being stimulated
with known ligands following a degree of chronic
oestrogen stimulation. G-protein expression was sub-
sequently established using Western blot analysis.
2.3. Primary mouse calvarial osteoblast cultures
Mouse osteoblast-like cells (MOBs) were isolated
by neonatal calvarial digest and characterized as pre-
viously described [21]. Brie£y, neonatal mouse cal-
variae were stripped of periosteal and endosteal tis-
sue, and minced in minimal essential medium
(MEM), washed twice in Tyrodes (Ca2/Mg2 free)
and sequentially digested; trypsin (1 mg/ml, 10 min),
dispase (2 mg/ml, 20 min), bacterial collagenase
(2 mg/ml, twice for 30 min). The supernatants from
both collagenase digestions were combined, cells re-
covered and re-suspended in phenol-red-free RPMI
1640 medium (RPMI 1640) which was supplemented
with 10% CSFCS and antibiotics. The cells were
plated 3U104/cm2 on tissue culture plastic in 75 cm2
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£asks, producing approx. 106 cells/£ask. 17L-E2
(1U1038 M) was added to pre-con£uent experimen-
tal cultures for 48 h. Cultures were washed and 17L-
E2 withdrawn from some cultures giving three series,
as follows: continuous addition of oestradiol (+/+),
17L-E2 withdrawn after 48 h (+/3) and without 17L-
E2 (3/3) in RPMI 1640 medium plus 10% CSFCS
(Fig. 1; this allowed n = 10 £asks/G-protein). For the
Western blot analysis cultures were stimulated for
the ¢nal 48 h with IL-6 (1U10310 M) or remained
unstimulated. Cultures for cAMP analysis had
100 WM 3-isobutyl-1-methylxanthine (IBMX) added
for 15 min before the addition of IL-6, which in turn
was added for 15 and 30 min. For the IP3 investiga-
tion cells were maintained in inositol- and serum-free
medium containing 12 mM lithium chloride for
15 min prior to the addition of IL-6 for 20 s. For
both IP3 and cAMP each stimulus was performed in
triplicate.
2.4. Preparation of plasma membranes
Cells were washed twice with ice-cold phosphate-
bu¡ered saline, pH 7.4, then scrapped o¡ into ice-
cold extraction bu¡er (10 mM Tris-HCl, 0.1 mM
EDTA, pH 7.8, containing proteinase inhibitors,
(Complete, Boehringer Mannheim, Germany) and
the membranes isolated as previously described
[27]. Cells were ¢rst homogenized (20U19 g needle
and 25U26 g needle), then sonicated on ice for 1 min
and the resulting homogenates were centrifuged for
15 min at 1500Ug (4‡C) to remove the nuclei. The
remaining homogenate was centrifuged at 40 000Ug
for 2 h at 4‡C, and the pellet containing the plasma
membrane was re-suspended in extraction bu¡er and
stored at 380‡C. Protein was determined as previ-
ously described [22].
2.5. Protein separation and immunoblotting
Individual proteins from the membrane prepara-
tions were separated (at 50 Wg protein) by SDS-poly-
acrylamide gel electrophoresis (12% resorbing gel) in
125 mM Tris-HCl, pH 6.8 [23]. The proteins were
electrophoretically transferred to nitrocellulose mem-
brane (0.45 Wm, Immunobilon-P, Millipore) in Bio-
Rad Mini Trans-Blot Cells. Transfer was performed
for 1 h at 100 V in 25 mM Tris-glycine bu¡er, pH 8.4
containing 20% methanol. Non-speci¢c binding to
nitrocellulose was prevented by incubating the mem-
brane with 5% bovine serum albumin (BSA) in
10 mM Tris-HCl-bu¡ered saline pH 7.6+0.05%
Fig. 1. A summary of the protocol for the stimulated MOBs used for IP3, cAMP, and Western blot analysis.
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Tween 20 (TBST) for 24 h at 4‡C. The membranes
were given three washes in TBST for 30 min, fol-
lowed by incubation with the appropriate primary
antibody in TBST with 5% BSA (1/1000) for 1 h
on a shaker at room temperature. The primary anti-
bodies used were GiK-, GsK-, and GqK-proteins,
PLCL1 and PLCL2, and actin (Santa Cruz Biotech-
nology, USA). Unbound antibodies were removed by
three washes with TBST; the antibodies bound to
nitrocellulose were detected using horseradish perox-
idase-conjugated goat anti-rabbit IgG (Santa Cruz
Biotechnology, USA) diluted at 1/2500 in TBST
and 5% BSA. The antigens were detected with an
ECL chemiluminescence kit (Amersham, UK) fol-
lowing the blot being sandwiched between plastic
sheets (overhead transparency, 3M Corporation).
The blots were exposed to Hyper¢lm-ECL (Amers-
ham) for 30 s. High and low standard protein
markers (MW-SDS-70L and MW-SDS-6H; Sigma,
UK) were used to determine relative molecular
mass of the protein. Actin levels were detected in
each sample in order to standardize the protein con-
centration added.
2.6. Measurement of intracellular cAMP
Following treatment, the medium from the £asks
was aspirated and the cells scraped loose in ice-cold
PBS using a rubber policeman and counted. The cells
were then centrifuged (100Ug for 5 min, 4‡C) and
the cell pellets re-suspended in 200 Wl of ice-cold
cAMP extraction bu¡er (95% methanol, 20 mM
HCl) for 24 h at 320‡C. The samples were air-dried
under a vacuum centrifuge and then dissolved in
50 mM sodium acetate, pH 5.8, and stored at
320‡C until the assay was conducted. The cAMP
levels were measured by a enzyme immunoassay
(Amersham).
2.7. Measurement of the formation of IP3
Following stimulation with IL-6, the reaction was
terminated by replacing the medium with 10%
HClO4. The acid supernatant was treated with
100 Wl 10 mM EDTA, pH 7.0, and neutralized with
300 Wl of 1:1 (v/v) mixture of Freon (Sigma) and tri-
n-octylamine. This was then mixed and centrifuged
for 1 min at 2000Ug to separate the phases. The
upper phase contained the neutralized sample and
was removed and subjected to radioimmunoassay
for IP3 (Amersham).
3. Results
3.1. Immunoblot analysis of G-protein K subunits
Immunoblot analysis showed elevated levels for
17L-E2 withdrawal, with IL-6 extracts for GqK
(37 kDa) compared to the other plasma membrane
extract groups (Figs. 2A and 3A). The intensity of
GqK for IL-6 with continuous 17L-E2 was faint com-
pared to the control. Antibodies against GsK re-
vealed two immunoreactive bands (38 and 40 kDa).
For GsK the intensity of the control extract was high-
Fig. 2. Immunoblot of plasma membrane extracts from mouse
primary osteoblasts with anti-GqK- (A), GsK- (B), and GiK-pro-
tein (C), and actin (D) antibodies. Equal amounts of (50 Wg)
extracts were separated by SDS-PAGE on a 12% gel and im-
munoblotted as described in Section 2. Lanes: 1, control mem-
brane; 2, cell extracts stimulated with IL-6 (1U10310 M); 3,
cell extract stimulated with oestradiol for 48 h and oestradiol
withdrawn after 48 h, and stimulated with IL-6 for 48 h; 4, ex-
tract stimulated with continuous 17L-oestradiol and IL-6 for
48 h. The blots for each sample were performed in triplicate.
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er than 17L-E2 withdrawal band and for IL-6. A
faint band was seen for IL-6 with continuous 17L-
E2 (Figs. 2B and 3B). Plasma membrane extract
analysis for GiK showed that levels were increased
with oestradiol withdrawn compared to control and
IL-6 alone (Figs. 2C and 3C). GiK protein band was
not present in the continuous 17L-oestradiol plus
IL-6 extract. To standardize the levels of protein
added to each well, the levels of actin were measured
(Fig. 2DFig. 3D). Each analysis was performed a
minimum of three times.
Western blotting showed immunoreactive bands in
membrane fractions of MOBs for both PLCL1 (140
kDa) and PLCL2 (132 kDa), (Figs. 4A,B and 5A,B
respectively), but the various oestrogen conditions
did not e¡ect the levels of the enzymes compared
to the control.
3.2. cAMP analysis
We examined the e¡ects of 17L-oestradiol and
IL-6 on cAMP production, an important secondary
Fig. 3. The bands were examined by scanning the gel using a Hewlett Packard O⁄ceJetPro 1150C and the optical density (O.D.) de-
termined by Oast Tech 1-D Densitometry software (Gillingham, Kent, UK). The lanes are as in Fig. 2 and represent the O.D. of plas-
ma membrane extracts from mouse primary osteoblasts with anti-GqK- (A), GsK- (B), and GiK-protein (C), and actin (D) antibodies.
Each value represents the mean þ S.E.M. of triplicate cultures. NS, not signi¢cant; *signi¢cantly di¡erent from control (P6 0.05);
**signi¢cantly di¡erent from control (P6 0.01). The data were analysed by Student’s t-test.
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messenger in osteoblasts. As shown in Fig. 6, stim-
ulation of the cells for 15 min with any of the ligands
had no e¡ect on cAMP production by the cultures.
IL-6 alone (7.0 pmol/1U106 cells) had no e¡ects on
cAMP production compared to the control (unstimu-
lated cells ; 7.0 pmol/1U106 cells) for 30 min stimu-
lation, but cAMP levels for MOBs that had 17L-E2
withdrawn (3.1 pmol/1U106 cells) were signi¢cantly
lowered compared to the control (P6 0.05). This
corresponded to the increased levels seen with GiK-
protein in similar oestrogen conditions. GiK-protein
is known to be an inhibitor of cAMP production. In
addition, the oestrogen withdrawal band for GsK-
protein was less intense than the control. This
G-protein is known to increase cAMP production
and this supports the reduction of cAMP, whereas
cells continuously stimulated with 17L-E2 for 30 min
produced higher levels of cAMP (16.1 pmol/1U106
cells ; P6 0.01) compared to the control.
3.3. IP3 analysis
As shown in Fig. 7, intracellular IP3 production
for all the cultures stimulated was signi¢cantly re-
duced (P6 0.05) compared to the control. However,
this reduction in IP3 was not due to oestradiol, but
to the cells being stimulated with IL-6.
4. Discussion
The precise mechanism by which oestrogen mod-
ulates bone behaviour has not been identi¢ed. When
examining bone morphologically, the e¡ects of oes-
trogen withdrawal or de¢ciency are well known. It is
characterized by accelerated bone resorption [5,24],
while advanced stages of post-menopausal osteo-
Fig. 4. Immunoblot of plasma membrane extracts from mouse
primary osteoblasts with anti-PLCL1 (A), and PLCL2 (B) anti-
bodies. Equal amounts of (50 Wg) extracts were separated by
SDS-PAGE on a 12% gel and immunoblotted as described in
Section 2. Lanes: 1, control membrane; 2, cell extracts stimu-
lated with IL-6 (1U10310 M); 3, cell extract stimulated with
oestradiol for 48 h and oestradiol withdrawn after 48 h and
IL-6 for 48 h; 4, extract stimulated with continuous 17L-oestra-
diol+IL-6. The blots for each sample were performed in tripli-
cate.
Fig. 5. The bands were examined by scanning the gel using a
Hewlett Packard O⁄ceJetPro 1150C and the optical density
(O.D.) determined by Oast Tech 1-D Densitometry software
(Gillingham). The lanes are as in Fig. 4 and are extracts from
mouse primary osteoblasts with anti-PLCL1 (A), and PLCL2
(B) antibodies. Each value represents the mean þ S.E.M. of trip-
licate cultures. NS, not signi¢cant; *signi¢cantly di¡erent from
control (P6 0.05); **signi¢cantly di¡erent from control
(P6 0.01). The data were analysed by Student’s t-test.
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porosis show a decrease in osteoblast number and
activity [25]. Conversely oestrogen therapy leads to
an overall gain of bone substance which is not
merely due to a reduction in bone loss, but by oes-
trogen directly stimulating osteoblasts. Studies have
shown that when oestrogen is applied to osteoblastic
and osteosarcoma cells it enhances synthesis of
DNA, type I procollagen, and TGF-L [26] as well
as cell proliferation [25]. In turn TGF-L has been
reported to induce bone formation [27,28]. Oestrogen
also reduces PTH-stimulated adenylyl cyclase activity
in osteosarcoma cells [29]. More importantly, bone
resorptive agents IL-1 and IL-6 are synthesized by
osteoblastic cells such as IL-1 and IL-6 with di¡erent
oestrogen conditions [6,30]. Oestrogen normally in-
hibits IL-1 and IL-6 production by osteoblasts, but
in pathological diseases where oestrogen depletion
occurs such as in osteoporosis these cytokine levels
are increased.
When examining the behaviour of osteoblasts
under the in£uence of oestrogen, there appear to be
two types of speci¢c outcome, i.e. genomic and non-
genomic e¡ects. The design of our experiments was
to examine the genomic e¡ects of the intracellular
signalling pathway. Speci¢cally we analysed the
long term e¡ects of oestrogen maintaining the G-pro-
tein pro¢le. A number of G-protein-coupled agonists
stimulate bone formation, leading to increases in
cancellous bone volume in animal models in normal
oestrogen conditions [13,14]. This study has docu-
mented that primary MOBs express GiK-, GqK-,
and GsK-proteins in the absence of oestrogen (con-
trol). But when oestrogen is present and then is with-
drawn, the levels of GiK- and GqK-proteins are ele-
vated; GsK levels are decreased. In the presence of
continuous oestrogen the levels of three G-proteins
are very low, indicating that in the normal environ-
ment when oestrogen is present the expression of
G-proteins is suppressed. But in pathological situa-
tions such as osteoporosis, when oestrogen becomes
depleted, there is no control on the expression of the
levels of G-proteins, particularly of GiK, the inhibi-
tory protein of cAMP. The speci¢c G-proteins be-
come elevated as shown in this investigation and,
therefore, the increased levels can a¡ect signal trans-
duction pathways further downstream in osteoblasts.
This was con¢rmed by the decrease in cAMP when
oestrogen was withdrawn, compared to the control,
Fig. 6. E¡ects of 17L-oestradiol on the levels of cAMP in
MOBs. Cells were cultured under various oestradiol conditions:
continuous 17L-oestradiol (+/+), 17L-oestradiol withdrawn after
48 h (+/3), and without 17L-oestradiol (control), then stimu-
lated with IL-6 for 15 and 30 min, as described in Section 2.
Each value represents the mean þ S.E.M. of triplicate cultures.
*Signi¢cantly di¡erent from control (P6 0.05); **signi¢cantly
di¡erent from control (P6 0.01). The data were analysed by
Student’s t-test.
Fig. 7. E¡ects of 17L-oestradiol and IL-6 on the formation of
IP3 in MOBs. Cells were cultured under various oestradiol con-
ditions: continuous 17L-oestradiol (+/+), 17L-oestradiol with-
drawn after 48 h (+/3), and without 17L-oestradiol (control),
then stimulated with IL-6 for 20 s, as described in Section 2.
Each value represents the mean þ S.E.M. of triplicate determi-
nations. *Signi¢cantly di¡erent from control (P6 0.05). The
data were analysed by Student’s t-test.
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and correlates with GiK- and GsK-protein results. It
is well established that this GiK inhibits adenylyl cy-
clase and so lowers the cAMP levels; GsK reduction
further argues for cAMP reduction. This has been
shown by other studies and by our data here. The
results showed that IL-6 does not modulate the ex-
pression of G-proteins in MOBs.
The chronic nature of oestrogen stimulation, in
particular the genomic consequences, can be impli-
cated by examining the types of receptors found for
oestrogen. These high a⁄nity oestrogen nuclear re-
ceptors (nER) are present in both osteoblasts [3] and
osteoclasts [4], suggesting that oestrogen can act di-
rectly on bone cells, and function as a ligand-indu-
cible transcription factor that modulates target gene
expression. These activated genes in£uence growth
and di¡erentiation of many cell types and tissues.
The nER is a member of the nuclear receptor super-
family that bind steroids [31]. The nER is composed
of distinct functional domains [32] which, on binding
oestrogen, interact with either a cognate classical oes-
trogen element (ERE) in the promoter region or me-
diate gene transcription via activator protein-1 (AP-
1) [33]. Recently a second nER beta (nREL) was
cloned from a rat prostate cDNA library [34] and
is present in bone [35]. The ¢rst identi¢ed nER has
been renamed nER alpha (nERK) [36].
To correlate these ¢ndings of G-protein activity
with actual functional changes of the cell, we exam-
ined further downstream cytosolic signalling path-
ways, that is cAMP and IP3.
The study showed that intracellular cAMP levels,
following stimulation, were signi¢cantly elevated by
the continuous presence of oestrogen, whereas the
withdrawal of oestrogen signi¢cantly inhibited
cAMP production by the osteoblasts, again following
stimulation. This has not been reported previously.
This correlates with an increased expression of GiK-
protein and decrease in GsK found in the blotting
analysis, which has been shown by many studies to
suppress cAMP level in di¡erent cells [9,37]. Elevated
levels of intracellular cAMP have been shown to be
connected to increased rates of proliferation and dif-
ferentiation in osteoblasts [38^40], and to increased
trabecular thickness [16]. cAMP also stimulates os-
teoblast precursors and induces bone formation by
PTH [41,42] and prostaglandins [18]. Therefore, the
increased levels of cAMP in the presence of contin-
uous oestrogen in osteoblasts correlates with other
studies in that active osteoblasts have high levels of
cAMP. Thus, in oestrogen depletion, the cAMP lev-
els are low as in this investigation and osteoblast
activity is reduced. It can be speculated that an im-
balance between bone resorption and bone formation
occurs as seen in osteoporosis as a consequence of
this inhibition.
The levels of intracellular IP3 production in the
osteoblast are not a¡ected by the varying oestrogen
conditions, although IL-6 did markedly reduce the
levels of IP3 compared to the control, probably via
gp130 signal transducer [43]. This would argue
against any downstream functional consequences of
the changes in GqK expression found in this study.
The study showed that primary MOBs express
phospholipase C isoforms L1 and L2, but the various
oestrogen protocols had no e¡ect on the level of ex-
pression of the PLCs examined by Western immuno-
blotting.
The purpose of examining cAMP and IP3 was to
establish whether the changing G-protein pro¢les
had any signi¢cance on functional activation of the
cell. The fact IP3 did not vary, but cAMP varied,
demonstrates that the changing G-protein expression
had modi¢ed a downstream signalling pathway and
thus modi¢ed cell activity.
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